Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients.
Gabrielle JongeneelMarjolein J E GreuterFelice N van ErningMiriam KoopmanGeraldine R VinkCornelis J A PuntVeerle M H CoupéPublished in: Therapeutic advances in gastroenterology (2020)
Our findings indicate that 3 months' adjuvant chemotherapy should be considered as standard of care in high-risk stage II CC patients for CAPOX, but not for FOLFOX.